H2 Global Group – Approval of the First SÚKL Clinical Trial for Molecular Hydrogen Inhalation
Molecular Hydrogen and Dementia Prevention: Czech Research Enters Its First Clinical Study
On 12 November 2025, a press conference of H2 Medical Technologies, part of H2 Global Group, was held at the ČTK PressCentre. At this event, we announced a major milestone – the approval of the first clinical study by the State Institute for Drug Control (SÚKL) in the Czech Republic, focused on inhalation of molecular hydrogen in patients with mild cognitive impairment (MCI).